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YopM, a protein toxin of Yersinia pestis, is necessary for virulence in a mouse model of systemic plague. We
previously reported YopM-dependent natural killer (NK) cell depletion from blood and spleen samples of
infected mice. However, in this study we found that infection with Y. pestis KIM5 (YopM) caused depletion of
NK cells in the spleen, but not in the liver, and antibody-mediated ablation of NK cells had no effect on
bacterial growth. There was no YopM-associated effect on the percentage of dendritic cells (DCs) or polymor-
phonuclear leukocytes (PMNs) in the early stage of infection; however, there was a YopM-associated effect on
PMN integrity and on the influx of monocytes into the spleen. Ablation of Gr1 cells caused loss of the growth
defect of YopM Y. pestis in both the liver and spleen. In contrast, ablation of macrophages/DCs inhibited
growth of both parent and mutant bacteria, accompanied by significantly fewer lesion sites in the liver. These
results point toward PMNs and inflammatory monocytes as major cell types that control growth of YopM Y.
pestis. Infection with fully virulent Y. pestis CO92 and a YopM derivative by intradermal and intranasal routes
showed that the absence of YopM significantly increased the 50% lethal dose only in the intradermal model,
suggesting a role for YopM in bubonic plague, in which acute inflammation occurs soon after infection.
Yersinia pestis, the infective agent of bubonic and pneumonic
plague, has caused widespread loss of human life during re-
current pandemics. Y. pestis still infects rodent populations in
large geographic zones where Y. pestis is endemic, and there
are cases of human plague reported annually (15, 19, 56). Y.
pestis and the closely related food-borne pathogens Yersinia
pseudotuberculosis and Yersinia enterocolitica share a 70-kb
plasmid carrying genes that encode a major set of proteins
involved in pathogenic properties that compromise the host
immune system (60). These include a type 3 secretion system
(T3SS) that at mammalian body temperature delivers a set of
six Yersinia outer protein (Yop) effector proteins into host cells
once the bacteria contact host target cells. Enzymatic and
cell biological mechanisms of five of the Yops, YopH, YopE,
YopT, YpkA/YopO, and YopJ, have been elucidated. YopJ
interferes with signal transduction through acetyltransferase
activity but is not required for virulence in either a mouse
model of systemic plague (57) or mouse and rat models of
bubonic plague (28, 65). In tissue culture infection models,
YopH, YopE, YopT, and YopO have been shown to antagonize
focal complex formation and activity of Rho family GTPases and
synergistically inhibit phagocytosis by mammalian cells. YopH
and YopE have been shown to be crucial for lethality in a
mouse model of systemic plague (intravenous [i.v.] infection),
and a yopH strain is attenuated for both bubonic and pneu-
monic plague (9). In addition, Y. pestis virulence proteins, such
as the surface fibrils F1 and PsaA, have antiphagocytic effects
and also have been found to contribute to virulence in systemic
plague (7, 31). Accordingly, Y. pestis is believed to exist pre-
dominantly in an extracellular location in vivo, although ini-
tially the bacteria might invade resting tissue macrophages
(Ms) and dendritic cells (DCs), based on assays of mouse
spleens in the systemic phase of bubonic plague (33). The
intracellular versus extracellular locations of Y. pestis during
the peripheral phases of plague on skin or in the lung have not
yet been studied.
It is believed that tissue Ms, DCs, and polymorphonuclear
leukocytes (PMNs) are early target cells for Yop delivery in
vivo, because these cells are present before or soon after in-
fection begins and function to initiate the innate defenses that
are undermined by Yops. Consistent with this hypothesis, Y.
pestis has been found in association with alveolar Ms early
during lung infection of mice (6) and likewise in association
with Ms, DCs, and PMNs in the spleens of mice infected i.v.,
and YopM can be injected into these cells (34). However, it is
becoming clear that spleens and lungs present distinctly differ-
ent inflammatory environments when infected by Y. pestis, with
PMNs migrating rapidly into spleens infected by the i.v. route
but not appearing in lungs until 36 h after intranasal (i.n.)
infection (27, 58). Accordingly, some virulence properties re-
quired for lethality of systemic plague are not required in
pneumonic plague. Examples are the capsular fibril F1 and the
antiphagocytic adhesin PsaA (7, 11, 12). There is no informa-
tion yet on the target cells or relative importance of Yops other
than YopH in pneumonic or bubonic plague.
The sixth effector Yop, YopM, is essential for virulence in
the mouse model of systemic plague: in C57BL/6 mice, a
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YopM strain of Y. pestis KIM5 is reduced in lethality by at
least 4 orders of magnitude (29). However, the function of
YopM has not been defined. YopM is a 46.2-kDa acidic pro-
tein made up almost entirely of 15 repeats of a 19-residue
leucine-rich repeat motif (30). The YopM monomer is horse-
shoe shaped and has the potential to form tetramers in which
the monomers stack together to form a hollow cylinder; how-
ever, the form that YopM assumes within the mammalian cell
is not known (16). After delivery to the host cell cytoplasm,
YopM localizes to the nucleus in a process that is facilitated by
vesicular trafficking (53). YopM was reported to form a com-
plex with the serine/threonine kinases PRK2 (protein kinase
C-related kinase 2) and RSK1 (90-kDa ribosomal S6 kinase) in
HEK293 cells infected with Y. pseudotuberculosis (36), leading
to activation of both kinases. However, the biological signifi-
cance of this complex is not known. There is no visible effect of
delivery of YopM into cultured cells, and microarray analysis
of M-like cell lines infected with Y. enterocolitica having or
lacking YopM also has not yielded any clue to YopM’s mech-
anism of action (21, 50).
Because these and other in vitro approaches to defining the
pathogenic mechanism of YopM have not been fruitful, we
have begun to characterize YopM’s effects in vivo. Previously
we found that YopM was still required for lethality in i.v.
infected SCID mice, showing that YopM’s virulence mecha-
nism does not require B or T cells and indicating that early in
systemic plague, YopM’s main function is to counteract a com-
ponent of innate immunity (25). A striking YopM-specific ef-
fect during systemic plague in wild-type C57BL/6 mice was the
depletion of natural killer (NK) cells from the spleen and a
reduction of NK cell numbers in blood, suggesting that YopM
might cause a loss of the NK cell compartment during systemic
plague. Correlated with this effect, there was a YopM-associ-
ated loss of mRNA for gamma interferon (IFN-) by NK cells
in infected spleens and diminished expression of mRNAs in
splenic Ms for cytokines that are required for viability and
activation of NK cells (interleukin 15 [IL-15], IL-18, and IL-
12). These findings supported the hypothesis that YopM may
function to inhibit IFN-mediated activation of Ms through
the depletion of NK cells (25).
In this study, we tested the hypothesis that NK cells are
critical for controlling Y. pestis pathogenesis early in plague
and that NK cells are the primary target of YopM. We char-
acterized infection dynamics and leukocyte populations in both
the liver and spleen during systemic plague in mice ablated for
Ms/DCs or for Gr1 cells. The data point to PMNs and
inflammatory monocytes as critical cells affected by YopM and
to Ms/DCs as an important early reservoir for bacterial
growth. Consistent with a role in undermining acute inflam-
mation, YopM was found to be important for the lethality of
bubonic plague, but not pneumonic plague.
MATERIALS AND METHODS
Bacterial strains and in vitro cultivation. Bacterial strains and plasmids used
in this study are listed in Table 1. This study employed strains from the two most
recently evolved groups of Y. pestis populations (1), Y. pestis KIM5 (molecular
grouping 2.MED), an isolate from Iran, and Y. pestis CO92 (1.ORI), isolated
in the United States and representative of strains causing the current pandemic.
The genomes of both strains have been sequenced (13, 43). Y. pestis KIM5 and
the yopM1 derivative KIM5-3002, in which the yopM ORF (including the stop
codon) and 2 bp upstream were deleted, lack the chromosomal pgm locus and are
conditionally virulent: they are attenuated by peripheral routes of infection but
are virulent by the i.v. route of infection, which bypasses the requirement for a
siderophore-based iron acquisition mechanism encoded in this locus (25, 61). Y.
pestis CO92.S6 is fully virulent.
Escherichia coli was routinely grown in Luria-Bertani broth or agar (38) at
37°C. Y. pestis KIM5-derived strains were routinely grown at 26°C in heart
infusion broth (HIB) (Difco Laboratories) and harvested in exponential phase at
an A620 of 0.8 to 1.2. Cells were centrifuged at 23,281  g and 4°C for 5 min,
washed, and diluted in phosphate-buffered saline (PBS). Samples of the diluted
cells were plated on tryptose blood agar (Difco Laboratories) and incubated at
30°C for 2 days to determine the dose. Y. pestis CO92-derived strains were grown
at 28°C or 37°C as indicated in HIB supplemented with 2.5 mM CaCl2 and 0.2%
TABLE 1. Bacterial strains and plasmids used in this study
Bacterial strain or plasmid Relevant properties Source and/orreference
Y. pestis strains
KIM5 Pgm Lcr; pCD1 pMT1 pPCP1; conditionally virulent pgm strain;
molecular grouping 2.MED; also called KIM D27
R. R. Brubaker
KIM5-3002 yopM1 derivative of KIM5; yopM coding sequence deleted from 2 bp
upstream of Met through the translational stop codon
25
CO99-3015.S6 CO92 Apr pgm Lcr pFra, pPCP2; contains pCD2Ap Spencer Leigh; 18
CO99-3015.S11 CO92 Apr pgm Lcr (pCD2 yadA::bla yopM2) pFra pPCP2; yopM and its
promoter of pCD2Ap deleted from 197 bp upstream through 1 bp after the
translational stop codon
This study
CO92.S1 Pgm Lcr pFra pPCP2; Lcr derivative of virulent Y. pestis CO92; molecular
grouping 1.ORI
Luther Lindler
CO92.S6 CO92 Apr Pgm Lcr pFra, pPCP2; reconstituted virulent strain made by
introduction of pCD2Ap into CO92.S1
18
CO92.S19 Reconstituted Lcr yopM2 strain made by introducing pCD2Ap yopM2
from CO99-3015.S11 into CO92.S1
This study
E. coli strain DH5 pir recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 deR (lacZYA-argF)U169 pir Lab stock
Plasmids
pLD55 Suicide vector with oriR6K and fusaric acid selection; Ap
r Tcr 37
pyopM-2 pLD55 containing the 1,180-bp left flank DNA upstream of the yopM2 locus
fused to the 1,230-bp right flank DNA downstream of yopM2
This study
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xylose; when the Lcr plasmid pCD2 was present, 50 	g/ml carbenicillin (Cb) was
also present. The cultures were diluted in PBS before the mice were infected.
Samples of the cell cultures and appropriate serial dilutions were plated on HIB
supplemented with Cb, and the number of CFU was determined after incubation
for 2 days at 28°C. The presence of the pigmentation locus (44) in all Pgm
strains was confirmed by the formation of red colonies on Congo red agar (59)
at 28°C. The presence of a functional Lcr virulence plasmid was confirmed by
absence of growth at 37°C on HIB agar supplemented with 0.2 M MgCl2 and 0.2
M sodium oxalate and by the Lcr phenotype (44) in defined medium TMH (57).
To create pCD2Ap yopM2, the yopM open reading frame (ORF) and 197
upstream bases containing the yopM promoter (48) were deleted from pCD2Ap
of the Y. pestis CO92 derivative Y. pestis CO99-3015.S6. Briefly, primers LF up
(5
-ACATTAGAGCTCTGCCTGTCTCCGTTGTTG-3
) and LF down (5
-TA
CTATCTGCAGTGTATGGCCGCAGAGT-3
) were used to copy 1,180 bp of
DNA upstream of the deleted locus by PCR, and primers RF up (5
-TGCTGC
AGACGCAAGAGCGTTCAT-3
) and RF down (5
-ATCTCTCGAGACGCC
ACCGTTGATTA-3
) were used to copy 1,230 bp of downstream DNA. The
upstream and downstream DNAs were cloned into pLD55 as respective SacI/PstI
and PstI/XhoI PCR products to create the allelic exchange plasmid pyopM-2 in
Escherichia coli DH5 pir. The deletion was moved into pCD2Ap by allelic
exchange as previously described (37, 42). The deletion did not remove any
ORFs other than yopM, and its upstream boundary was 196 bp downstream from
the stop codon of the nearest potential ORF (48). The deletion extended 1 bp
downstream of the yopM stop codon (similar to the yopM1 mutation in Y. pestis
KIM, which deletes the stop codon but no downstream bases). The resulting
yopM deletion was confirmed by PCR. The absence of YopM expression in the
yopM2 strain but normal levels of expression and secretion of YopH and LcrV
with appropriate regulation by calcium in the medium were confirmed by im-
munoblot analysis of whole cells and culture supernatants. Strains with the two
mutations, yopM1 in the KIM5 background and yopM2 in the CO92 back-
ground, are believed to have the same phenotypes, because the mutations are
both well separated from upstream and downstream ORFs, but because they are
not identical, we have given them different allelic designations.
pCD2Ap yopM2 was moved into Y. pestis CO92.S1 by electroporation of total
plasmid DNA from Y. pestis CO99-3015.S11 in biosafety level 3 containment.
Transformed strains were selected for Cb resistance and screened for the Pgm
and Lcr phenotypes. Pgm Lcr isolates were subcultured at 26°C with shaking
at 200 rpm in TMH plus Cb for ca. 10 generations and then for 2 h in TMH with
or without 2.5 mM CaCl2 (no Cb); then they were incubated at 37°C for 4 h. Cells
and culture medium were analyzed by immunoblotting for expression and secre-
tion of Yops as described previously (45). The resulting Y. pestis strain CO92.S19
and the YopM strain CO92.S6 were handled only in biosafety level 3 contain-
ment with select agent security.
Infection of mice and measurement of bacterial viable numbers in tissues. All
animal experiments in this study were reviewed and approved by the University
of Kentucky Institutional Animal Care and Use Committee. For studies with Y.
pestis KIM5 and KIM5-3002, female C57BL/6N.HSD mice (Harlan Sprague
Dawley, Inc.), 6 to 8 weeks old, were anesthetized with an isoflurane-oxygen
mixture by a rodent anesthesia machine. Fifty microliters (400 CFU) of bacterial
suspension was injected in each mouse i.v. via the retro-orbital plexus. This was
above the 50% lethal dose (LD50) for the parent strain and below that for the
yopM1 mutant. The two bacterial strains grew similarly for the initial 24 to 48 h
of infection (25) (see Fig. 1); accordingly, the innate host responses were elicited
by similar bacterial numbers, and differences would be due to the presence or
absence of YopM and not to nonspecific factors. Groups of three mice per strain
per time point were humanely killed by CO2 inhalation followed by cervical
dislocation, and their spleens and livers were weighed, transferred to a sterile bag
containing 5 ml of PBS, and placed on ice. The tissues were homogenized in a
Stomacher 80 lab blender (Tekmar Co.) for 60 s with high speed. The liver and
spleen homogenates were diluted in PBS and plated to measure the bacterial
burden in the organs.
For infection with Y. pestis CO92 strains, the mice were anesthetized with
ketamine (100 mg/kg of body weight; IVX Animal Health) and xylazine (10
mg/kg; Butler Co.) given intraperitoneally (i.p.). Bacterial doses were made in
100 	l of PBS for intradermal (i.d.) infection and administered with a 1-ml
tuberculin syringe fitted with a retractable 26-gauge needle (Becton Dickinson
and Company). For i.n. infection, a 20-	l volume of bacteria in PBS was instilled
into the nares from a plastic micropipette tip. The effect of xylazine was then
reversed by subcutaneous injection of yohimbine (2 mg/kg) (Ben Venue Labo-
ratories), and the mice were treated with an optical lubricant before being
returned to their cages.
Tests of virulence in mice. To determine LD50 values, groups of mice were
infected by the i.n. or i.d. route with 3.2-fold increasing doses of YopM parent
or yopM mutant strains, for which the series of doses were chosen to lie within
a range determined by preliminary pilot tests. The mice were monitored daily for
14 days for signs of illness and mortality. Mice were killed humanely if they were
deemed unlikely to survive to the next observation time point and counted as
though they were dead at the next observation point. The criteria for humane
killing were loss of the righting reflex or immobility accompanied by hunched
posture, ruffled fur, and heavy breathing.
Innate immune cell ablation. NK cell ablation was mediated by mouse anti-
NK1.1 monoclonal antibody (MAb) PK136 (immunoglobulin G2a [IgG2a]) pre-
pared by injecting the B-cell hybridoma PK136 clone (American Type Culture
Collection) i.p. into pristane-primed BALB/c mice. Ascitic fluid samples were
clarified by centrifugation and stored at20°C. Before injection, antibodies were
again centrifuged and then filtered through a 0.22-	m-pore-size low-protein-
binding membrane (Millipore). Anti-NK1.1 MAb or rat IgG (Sigma-Aldrich
Chemical Co.) was injected i.p. at 1 mg/mouse on days 1, 1, and 3 of Y. pestis
infection. Flow cytometric analysis of NK cells and other cells bearing the NK1.1
marker (NK-T cells and NK-DCs) in these mice and in mock-treated mice
employed the same anti-NK1.1 antibody as well as antibody against the so-called
“pan-NK” cell marker DX5. Control tests showed that following the ablation
treatment, there were no cells with surface-bound IgG2a—i.e., no NK cells were
present, but cells were obscured from detection by having their NK1.1 epitope
blocked with the non-fluorochrome-coupled anti-NK1.1 used for ablation (de-
termined by flow cytometry after staining for surface IgG2a with fluorescein
isothiocyanate [FITC]-conjugated rat anti-mouse IgG2a; data not shown).
Ablation of PMNs and inflammatory monocytes was done as described previ-
ously (49). Briefly, anti-Gr1 MAb (which recognizes both populations of cells as
well as memory CD8 T cells, plasmacytoid DCs, and other small populations of
regulatory myeloid cells [14]) was prepared from B-cell hybridoma line R6-8C5
(DNAX Research Institute) and partially purified using ammonium sulfate pre-
cipitation. Anti-Gr1 MAb or rat IgG was injected i.p. at 100 	g/mouse on days
1 and 1 of Y. pestis infection. Flow cytometric analysis of PMNs in these mice
and in mock-treated mice employed MAb 1A8, which detects a PMN-specific
Ly6G epitope that is distinct from the common epitope on Ly6G and Ly6C that
is detected by MAb R6-8C5. Ms/monocytes were analyzed as Ly6G CD11b
cells that did not carry the DC marker CD11c.
Systemic ablation of Ms/DCs was mediated by liposome-encapsulated clodr-
onate (clodronate-liposomes). The liposomes were prepared as previously de-
scribed (62). Dichloromethylene diphosphonate (clodronate) was a gift of Roche
Diagnostics GmbH, Mannheim, Germany. Phosphatidylcholine was obtained
from Lipoid GmbH, Ludwigshafen, Germany. Cholesterol was purchased from
Sigma-Aldrich. Mice in ablation groups or control groups were injected, respec-
tively, with 200 	l clodronate-liposomes or liposome-encapsulated PBS (PBS-
liposomes) by the i.v. route into the retro-orbital plexus 18 h prior to Y. pestis
infection and on day 1 postinfection (p.i.). The extent of ablation was evaluated
by flow cytometry with analysis for CD11b (Ms, monocytes, PMNs, some DCs),
CD11c (mainly DCs), and Ly6G (mainly PMNs).
Two tests employed transgenic MaFIA (M Fas-induced apoptosis) mice on
a C57BL/6 background (10). These mice were bred and confirmed by PCR to be
homozygous for the inducible suicide transgene before use in experiments. Mice
were between 5 and 8 weeks old. Both sexes were used and distributed equally
among treatment groups. These mice can be ablated for cells of the M/DC
lineage by treatment with the dimerizer drug AP20187 (gift of Ariad Pharma-
ceuticals, Inc.). Seven days prior to infection, the ablation regimen was initiated
by i.v. injection of 10 mg/kg of dimerizer drug or mock injection solution (water
containing 4% [vol/vol] ethanol, 10% [wt/vol] PEG 400, and 1.7% [vol/vol]
Tween 20). Injection was done within 30 min of dilution of dimerizer into the
injection solution, and the volume, adjusted by body weight, averaged 100 	l per
mouse. The mice received daily injections of drug or mock injection solution for
5 days and then were allowed to rest for 2 days before they were infected with Y.
pestis KIM5. The extent of ablation was evaluated by flow cytometry with analysis
of CD3 cells (non-T cells) for Gr1 (inflammatory monocytes and PMNs, some
DCs) and F4/80 (Ms and monocytes).
Flow cytometry. Cells isolated from livers and spleens were analyzed in a
FACSCalibur flow cytometer (Becton Dickinson FACS Systems). Briefly, the
spleens were placed in sterile bags containing 5-ml volumes of PBS and then
processed with the Stomacher 80 lab blender for 60 s at high speed. The ho-
mogenate was centrifuged (913  g for 10 min) and resuspended in 2 ml red
blood cell (RBC) lysis buffer (150 mM NH4Cl [pH 7.2]). After 2 min, the reaction
was terminated by the addition of 8 ml of PBS. The cell suspensions were filtered
through a 40-	m-pore-size cell strainer (Becton Dickinson and Company) to
remove connective tissue, centrifuged (913  g for 10 min), and resuspended in
PBS containing 1% (wt/vol) bovine serum albumin (BSA) and 0.1% (wt/vol)
sodium azide (PBS-BSA-azide).
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To process livers, finely minced livers were placed into sterile bags containing
10-ml volumes of RPMI 1640 (Life Technologies Inc.) with 10% fetal bovine
serum (ATCC) and processed with the Stomacher 80 lab blender for 60 s with
high speed. The homogenates were incubated with DNase I (160 U/ml; Sigma-
Aldrich) and collagenase (400 U/ml; Invitrogen) for 30 min in a 37°C water bath
with shaking at 125 rpm. After filtration through a 40-	m-pore-size cell strainer,
cell suspensions were washed once with ice-cold PBS-BSA-azide and resus-
pended with 5 ml of 33.8% Percoll (Amersham Bioscience, GE Healthcare),
followed by a 12-min centrifugation at 693 g. The cells in the bottom layer were
collected, washed with PBS, and treated with RBC lysis buffer. Nonlysed cells
were resuspended in PBS-BSA-azide.
The following antibodies were purchased from BD Pharmingen, Inc.: allophy-
cocyanin (APC)-conjugated anti-CD11c, APC-conjugated anti-NK1.1, APC-con-
jugated anti-CD62L, FITC-conjugated anti-CD3, FITC-conjugated anti-CD11b,
FITC-conjugated anti-DX5 (CD49b), FITC-conjugated anti-mouse IgG2a,
indodicarbocyanine- or APC-conjugated anti-F4/80, phycoerythrin (PE)-conju-
gated anti-B220, PE-conjugated anti-CD8, PE-conjugated anti-DX5, PE-conju-
gated anti-Ly6G, PE-conjugated anti-NK1.1, PE-conjugated anti-CD86, PE-con-
jugated anti-Gr1 and PE-conjugated anti-Iab. To gate out apoptotic or dead cells,
ethidium monoazide (Sigma) was used for viability staining. To evaluate NK-T
cells, mCD1d/PBS-57 (mouse CD1d loaded with PBS-57, an analogue of -galac-
tosylceramide) (APC conjugated) was used (provided by the NIH Tetramer Core
Facility).
Prior to staining, the cells were counted, and samples were adjusted to 5  105
cells per 100 	l. All samples were stained with ethidium monoazide to identify
dead cells. In the presence of the appropriate combinations of antibodies, the
cells were incubated on ice for 30 min, with the last 10 min of incubation in the
light. After the cells were washed in PBS, they were resuspended in ice-cold PBS
containing 4% (wt/vol) paraformaldehyde (pH 7.4) and treated at least 30 min
before flow cytometric analysis. Flow cytometric processing was performed by
the Flow Cytometry Core Facility at the University of Kentucky. Software
WinMDI (version 2.7; Joseph Trotter, Salk Institute for Biological Studies, La Jolla,
CA [available at http://facs.Scripps.edu/software.html]) was used to analyze the
data. To measure the level of expression of each cellular surface marker, the
mean fluorescence intensity (MFI) of the fluorochrome conjugated to this mark-
er’s MAb was used. Typical leukocyte populations obtained by these methods
from noninfected mice are given in Table 2.
Histopathology. Portions of livers, skin, or lung were placed in 10% buffered
formalin, processed through graded series of alcohol and xylene solutions, and
then embedded in paraffin. Sections stained with hematoxylin and eosin were
examined and photographed with an Axiophot microscope (Carl Zeiss, Inc.).
Statistical analysis. Infection experiments with flow cytometric, histopathol-
ogy, and CFU analyses were conducted at least twice with at least three replicate
mice per group. The data from the replicate experiments were then pooled for
analysis of significance. Significance of differences among groups was assessed by
the Student unpaired two-tailed t test. Values for which P  0.05 were consid-
ered significant. Data are presented as the mean values  standard deviations
(SDs), and the numbers of mice used for each datum point are given in the figure
legends. Virulence tests measuring lethality were conducted at least twice with
four to eight mice per group and three or four dosage groups. Probit analysis was
applied to log-transformed pooled data (17; implemented through BioStat 2008
5.1.1.0 [by A. Simachov at AnalystSoft]), and the results are expressed as the
mean  standard error of the mean with 95% confidence limits given in paren-
theses.
RESULTS
YopM-dependent NK cell depletion is delayed in the liver
than in the spleen. We are using a systemic model of plague to
identify differences in the early host response that are derived
from the presence versus absence of YopM in the infecting Y.
pestis strain. This model is relevant to the later phases of both
bubonic and pneumonic plague, when the bacteria disseminate
to the liver and spleen, and it offers the strong advantage of a
synchronous infection that can be readily quantified. The time
courses for growth of the parent Y. pestis KIM5 are similar in
the livers and spleens of mice with systemic plague, and the
timing of growth and clearance of the yopM1 mutant KIM5-
3002 are also similar for the two organs (25). We hypothesized
that the host mechanisms that control the growth patterns are
similar in the two organs. In previous work (25), several leu-
kocyte populations had been characterized in the spleens and
blood of mice with systemic plague, but these cells had not
been tested for their importance in limiting the growth of the
YopM mutant. In this work we sought to identify cell types
that were required for controlling growth of YopM Y. pestis
in the liver and spleen. We first tested whether the YopM-
specific NK cell depletion seen previously in spleen was truly a
global effect, occurring in the two major organs (liver and
spleen) colonized by Y. pestis early in systemic plague. Groups
of three C57BL/6 mice were infected i.v. with 400 CFU of Y.
pestis KIM5 or KIM5-3002. This dose was intermediate be-
tween the LD50s for these two strains (29). Organs were har-
vested on days 2, 4, and 5 p.i. Figure 1A shows that the growth
of the YopM mutant KIM5-3002 in the liver and spleen was
progressively slower and that the bacteria were cleared more
rapidly from both organs than the parent strain KIM5 was. In
spleens, a YopM-dependent loss of NK1.1 CD3 NK sub-
groups was observed during infection as previously reported
(Fig. 1B). Neither DX5 NK1.1 NK cells nor CD1d-re-
stricted NK-T cells showed any YopM-dependent changes,
although the percentages of these latter cells dropped by ca.
twofold between day 2 and day 4 p.i. in mice infected by either
Y. pestis strain (data not shown). In contrast, there was no
YopM-related depletion of any NK cell population in the liver
(Fig. 1C shows the major NK population in the liver). These
data indicated that YopM-specific depletion of NK cells was
not systemic and suggested that loss of NK cells may not be
critical for the virulence effect of YopM.
Antibody-mediated ablation of NK cells does not bypass the
yopM1 mutation. If NK cells are responsible for growth re-
striction of the Y. pestis yopM1 mutant strain, this growth
limitation should be relieved in mice lacking NK cells. We
tested this hypothesis by comparing the growth of parent and
mutant Y. pestis in mice ablated for NK cells. On day 1 prior to
infection and days 1 and 3 p.i., we i.p. injected anti-NK1.1 MAb
or rat IgG into each mouse in the ablation groups or mock
treatment groups, respectively. Mice were then infected by the
i.v. route with 400 CFU and humanely killed on days 2, 4, and
5 p.i. for analysis of CFU, leukocyte populations, and histopa-
thology in spleen and liver. About 90% of NK1.1 CD3 cells
were ablated from both the spleen and liver by the initial
antibody treatment, and the subsequent treatments maintained
very low levels of NK cells during the experiment (Fig. 2A).
However, successful NK cell ablation failed to relieve the re-
TABLE 2. Average populations of total leukocytes, PMNs, Ms,
NK cells, and DCs obtained from the spleens and livers of
uninfected micea
Organ
Total no. of cells (106) per organ
Leukocytes
PMNs
(Ly6G
CD11b
F4/80)
Ms
(Ly6G
CD11b
F4/80)
NK cells
(NK1.1
DX5
CD3)
DCs
(CD11c)
Spleen 110.7  9.5 9.3  0.5 5.5  2.9 7.4  1.5 4.5  0.9
Liver 8.9  0.3 0.29  0.03 0.79  0.05 0.73  0.08 1.2  0.25
a For individual mice, the percentage of total splenic or liver leukocytes for
each cell type was determined by flow cytometry as described in Materials and
Methods, and the average  standard deviation was determined for the replicate
mice.
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stricted growth of the Y. pestis KIM5-3002 yopM1 mutant in
either organ (Fig. 2B). Histopathological analysis of the livers
(day 4 p.i.) in both the KIM5-3002-infected mock-treated or
NK cell-ablated mice showed lesions that were similar in char-
acter and number (Fig. 2C). The histopathological appearance
was typical of the proinflammatory response that precedes
microgranuloma formation in C57BL/6 mice, curbing net
growth of the yopM1 mutant (25). While it is conceivable that
the NK cells remaining in the anti-NK1.1 MAb-treated mice
(10%) were sufficient to exert full growth limitation of the
yopM1 mutant, we consider it more likely that YopM-depen-
dent NK cell depletion may be a side effect caused by the
compromised function of other cell types, such as Ms and
DCs, in the spleen (25).
Population dynamics of other innate defense cells during
systemic plague. Since NK cells did not prove to be a target of
YopM that was critical for virulence, we evaluated leukocyte
population dynamics for clues that would point to the cells that
are responsible for the in vivo growth defect of YopM mutant
Y. pestis. Further, because of the large YopM-associated effect
on NK cells in the spleen, we performed this analysis in mice
ablated for NK cells as well as in mock-treated mice to learn
FIG. 1. Comparisons of bacterial CFU numbers and NK cell percentages in spleens and livers after infection of C57BL/6 mice with Y. pestis
KIM5-3002 (yopM1 mutant) or the parent Y. pestis KIM5. Mice were infected i.v. with 400 CFU of Y. pestis KIM5-3002 or KIM5 strain. (A to
C) At the indicated times p.i., the numbers of CFU in the spleen and liver (A) and the percentages of CD3 NK cells in leukocytes from the spleen
(B) or liver (C) were determined. Representative flow cytometric scatter plots illustrating the discrimination among cell populations on day 5 p.i.
(d5) in the spleen and liver, respectively, are shown to the right of panels B and C. The upper plot in panel B and the left plot in panel C are from
individual mice infected with Y. pestis yopM1 mutant strain, and the lower plot in panel B and the right plot in panel C are from individual mice
infected with the parent strain. The data in the graphs represent the averages plus SDs (error bars) for 14 mice per datum point for the spleen
and 11 mice per datum point for the liver, pooled from replicate experiments. In panel A and panels in all other figures showing CFU, the day
0 points give the total bacterial doses as determined by plating the inocula. Values that are significantly different (P  0.01) in the KIM5-3002-
and KIM5-infected groups are indicated ().
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FIG. 2. Anti-NK1.1 MAb-mediated NK cell ablation failed to relieve the growth defect due to the yopM1 mutation. Mice were given
anti-NK1.1 MAb (NK ablation groups) or rat IgG (mock ablation groups) i.p. 1 day before i.v. infection with 400 CFU of Y. pestis KIM5-3002
(yopM1 mutant) or the parent strain KIM5. The same doses of antibodies were also given to the mice on day 1 and day 3 p.i. (A and B) On days
2, 4, and 5 p.i., the percentages of CD3 NK cells (A) and numbers of CFU (B) in spleens and livers were determined. Representative scatter plots
showing the discrimination among cell populations in spleens on day 4 p.i. (d4) of mice infected with Y. pestis yopM1 mutant are shown to the
right in panel A. The scatter plots show the results for a mock-treated mouse and a mouse ablated of NK cells. The data in the graphs represent
the averages plus SDs (error bars) for six mice per datum point, pooled from replicate experiments. Values that are significantly different in the
NK cell-ablated and mock ablation groups of mice infected with KIM5-3002 are indicated as follows: †, P  0.05; ††, P  0.01. Values that are
significantly different in the NK cell-ablated and mock ablation groups of mice infected with KIM5 are indicated as follows: #, P  0.05; # #, P 
0.01. (C) Histopathology on day 4 p.i. in liver of NK cell-ablated and mock-treated mice infected with KIM5-3002. The top panels and the bottom
panels show typical lesions caused by KIM5-3002. Bars, 20 	m (top panels) and 100 	m (bottom panels).
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whether the absence of this important but apparently noncrit-
ical cell would unmask an effect of YopM on other cell types.
DCs were evaluated because they are present at portals of
microbial infection and in reticuloendothelial organs colonized
by Y. pestis, and their potent antigen presentation and surveil-
lance functions are important for both innate and adaptive
defenses against invading microorganisms. By flow cytometry
we evaluated the percentages of three major subgroups of
DCs, “conventional” CD11c DCs (CD11b or CD8) and
plasmacytoid CD11clo B220 DCs (2, 32) in mock-treated or
NK cell-ablated mice infected with the parent Y. pestis KIM5
or the yopM1 mutant. Figure 3 shows that in the spleens of
mock-treated mice (left panels), only CD8 DCs (Fig. 3B)
displayed a reproducible YopM-associated pattern of change
in which the numbers of these DCs declined significantly by
day 4 of infection by the parent Y. pestis strain but were
maintained in mice infected with the yopM1 mutant. NK
cell ablation did not affect the distribution of any of the DC
subgroups in the spleen. In the livers from mock-infected
mice (Fig. 3, right panels), all of the three DC subgroups
showed moderate YopM-related change after day 4 p.i., and
again, ablation of NK cells did not alter the distribution of DC
subgroups, with the exception of one time point for mice in-
fected with the parent Y. pestis. Staining for surface markers of
DC activation (CD86 and Iab) did not reveal any significant
differences between yopM1 mutant and parent Y. pestis infec-
tions (data not shown) as indicated by MFI.
Figure 4A shows that the percentage of PMNs (Ly6G
FIG. 3. Comparison of three DC subgroups in the livers and spleens of mice infected with Y. pestis KIM5-3002 (yopM1 mutant) or the parent
Y. pestis KIM5 with or without NK cell ablation. DCs were analyzed from the leukocyte populations obtained in the experiments shown in Fig. 2;
the symbols and lines are the same as in Fig. 2. Panels A, B, and C show CD11b DCs (10 and 14 mice per datum point for spleen and liver,
respectively), CD8 DCs (10 mice per datum point), and B220 DCs (11 mice per datum point), respectively, in the spleen and liver. A
representative flow cytometric scatter plot illustrating the discrimination among cell populations in the spleen on day 4 p.i. (d4) of a mouse infected
with the Y. pestis yopM1 mutant is shown to the right of each panel. The notations for statistically significant values are as in the legend to Fig.
2, with the addition of comparisons between groups of mice infected with KIM5 and KIM5-3002 (, P  0.01).
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FIG. 4. Ablation of Gr1 cells relieved the growth defect of the Y. pestis KIM5-3002 (yopM1 mutant). Mice were given anti-Gr1 (Ly6G/Ly6C)
MAb (Gr1 cell ablation groups) or rat IgG (mock ablation groups) i.p. 1 day before and 1 day after i.v. infection with 400 CFU of KIM5-3002
or the parent strain KIM5. (A to C) On days 1, 2, and 3 p.i., the percentage of PMNs (A) and Ms/monocytes (B) in leukocytes from spleens and
livers and numbers of CFU (C) in spleens and livers were determined. Representative scatter plots showing the discrimination among cell
populations in the spleens of noninfected and infected mice are shown to the right of panels A and B, respectively. In panel A, the top and bottom
plots show the respective cellular distributions on day 0 (d0) of the experiment for a mock-treated mouse and a mouse ablated of Gr1 cells. In
panel B, the top and bottom plots show the respective distributions on day 3 p.i. (d3) for mock-treated mice infected with the yopM1 mutant and
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CD11b) increased during infection of mock-treated mice by
both Y. pestis strains, peaking on day 2 p.i. Thus, the influx of
PMNs from blood was not affected by the presence of YopM
in the infecting strain. In contrast, there was a significant and
reproducible difference in the M/monocyte populations
(Ly6G CD11b) in the spleen on days 2 and 3 p.i., but this
was not observed in the liver (Fig. 4B). The cells in the peak
population had high expression levels of CD11b, when ana-
lyzed as MFI, and thus likely were newly arrived monocytes
(data not shown). Accordingly, the increase in Ms in mice
infected with the yopM1 mutant but not the parent Y. pestis
may reflect an effect of YopM on monocyte influx into the
spleen but does not obviously explain the virulence effect of
YopM in the liver.
Gr1 cells are necessary for the clearance of the yopM1
mutant strain. To evaluate the importance of PMNs and the
inflammatory monocyte subset of monocytes (20) in the patho-
genic mechanism of YopM, we ablated these cells in vivo with
anti-Gr1 (Ly6G/Ly6C) MAb given 1 day before and 1 day after
infection with the yopM1 mutant or the parent Y. pestis strain.
Figure 4A shows that the ablation protocol removed over 90%
of the Gr1 PMNs from both the liver and spleen, and Fig. 4B
shows that the increase in monocytes in both organs was also
abolished or delayed by anti-Gr1 treatment. In the mock-treated
mice, the YopM-associated growth defect was exhibited as ex-
pected at days 2 and 3 p.i. (Fig. 4C). Strikingly, the growth defect
of the yopM1 mutant strain in both the spleen and liver disap-
peared in the mice treated with anti-Gr1 antibody, and growth of
the parent strain was slightly enhanced (Fig. 4C).
The lesions in livers of mock-treated mice infected with
parent Y. pestis were dominated by dissipating acute inflam-
mation on day 3 p.i., whereas those from mice infected with the
yopM1 mutant contained large numbers of PMNs and Ms
(Fig. 4D, top panels) as described previously (25, 41, 58).
However, this histological picture appeared to be in conflict
with the results of whole-organ flow cytometry, which showed
no significant difference in the percentage of intact PMNs
(PMNs that did not stain with ethidium monoazide) in the
livers or spleens of mice infected with the two strains of Y.
pestis (Fig. 4A). To address this issue, we visually scored all the
lesions in the day 3 p.i. histopathological slides for number,
size, and character. We found that infection by the yopM1
strain caused fewer but larger foci than those by Y. pestis
KIM5. The foci in livers of mice infected by the YopM mu-
tant always contained morphologically intact PMNs, whereas
the livers from mice infected by the parent strain typically
contained a mixture of morphologically intact PMNs and cel-
lular debris (Fig. 4E, bottom panels; illustrated in higher mag-
nification by the top panels in Fig. 4D). The difference in the
foci between the two strains was clear by day 2 p.i. (Fig. 4E, top
panels), indicating that there was a YopM-associated differ-
ence in PMN integrity or function that correlated with the
difference in growth for the parent and YopM mutant strains.
After ablation of PMNs and inflammatory monocytes, le-
sions in mice infected by the Y. pestis yopM1 mutant morpho-
logically mimicked those of mice infected with the parent
strain (Fig. 4D, bottom panels). In general, ablation of Gr1
cells made the infection by the yopM1 mutant resemble in-
fection by the parent strain and implicated Gr1 cells as tar-
gets of YopM’s virulence effect.
Clodronate-sensitive Ms/DCs are essential for Y. pestis
growth. Resident Ms and DCs are believed to provide an
early intracellular niche for Y. pestis in the spleen (33). More-
over, the presence of YopM in the infecting Y. pestis had
previously been shown to be associated with decreased expres-
sion of proinflammatory cytokines, like tumor necrosis factor
alpha, IL-1, IL-12, IL-15, and IL-18, in F4/80 cells (Ms and
monocytes) by day 2 p.i. (25). Accordingly, it is possible that
these cells are the initial target of YopM and that PMNs and
inflammatory monocytes are affected secondarily. To test this
hypothesis, we treated mice by the i.v. route with clodronate-
containing mannosylated liposomes 18 h before and 1 day after
infection to specifically deplete Ms/DCs. The mock-treated
mice received liposome-encapsulated PBS. Flow cytometric
analysis showed that the clodronate treatment depleted ca.
80% of Ms (CD11b Ly6G CD11c) from the spleen and
prevented the net increase due to influx of inflammatory
monocytes (Fig. 5A). In the liver, clodronate failed to reduce
the initial number of M-like cells but prevented or delayed
the influx of monocytes (Fig. 5A). Flow cytometric analysis for
total CD11c DCs showed a depletion pattern similar to that
of Ms/monocytes (data not shown). Nonetheless, the clodr-
onate treatment strikingly curtailed the number of viable bac-
teria for both Y. pestis strains in both organs (Fig. 5C). This
effect did not correlate with changes in numbers of PMNs
except at day 3 and then only in the spleen (Fig. 5B). Lesions
at day 3 p.i. in the mock-treated mice were similar in appear-
ance to those of other mock-treated mice at the same time p.i.
(compare the top panels in Fig. 5D to the top panels in Fig.
4D). However, in clodronate-treated mice, regardless of the
strain they were infected with, only a few small lesions were
found, and there was little or no necrosis present. These his-
topathological findings were consistent with a lower inflamma-
tory status in the mice treated with clodronate-liposomes ver-
sus the mice treated with PBS-liposomes (Fig. 5D). These data
showed that clodronate-sensitive cells function to amplify bac-
terial numbers for Y. pestis with or without YopM, consistent
the parent strain. The data in the graphs represent the averages plus SDs (error bars) for six mice per datum point for panels A and B and nine
mice per point for panel C, pooled from replicate experiments. Values that are significantly different for the Gr1 cell-ablated and mock ablation
groups of mice infected with KIM5-3002 are indicated as follows: †, P  0.05; ††, P  0.01. Values that are significantly different for the Gr1
cell-ablated and mock ablation groups of mice infected with KIM5 are indicated as follows: #, P 0.05; # #, P 0.01. Values that are significantly
different for mock-treated groups of mice infected with KIM5 and KIM5-3002 are indicated as follows: , P  0.05; , P  0.01.Values that are
significantly different for Gr1 cell-ablated groups of mice infected with KIM5 and KIM5-3002 are indicated as follows: , P  0.05; , P  0.01.
(D and E) Histopathology in livers from mice that were ablated for Gr1 cells or mock treated and infected with KIM5 or KIM5-3002. Panel D
shows lesions from day 3 p.i. In panel E, differences in numbers and sizes of lesions caused by the two Y. pestis strains are illustrated for both day
2 and day 3 p.i. Bars, 20 	m (D) and 100 	m (E).
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FIG. 5. Ablation of Ms/monocytes with clodronate-liposomes restricted growth of both Y. pestis strains. Mice were given clodronate-liposomes
(M/monocyte ablation groups) or PBS-liposomes (mock ablation groups) by the i.v. route 18 h before i.v. infection with 400 CFU of Y. pestis
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with a previous study which suggested that Ms serve as an
intracellular reservoir during plague (33).
The liposomes per se are not completely benign, and the
total numbers of Ms were reduced in the spleens of mice that
were mock treated with PBS-liposomes. We consequently
tested a different method for M/DC ablation for its effect on
infection by the parent Y. pestis KIM5 strain. Ms/DCs can be
conditionally depleted by treating MaFIA mice with a dimer-
izer drug that initiates Fas-induced apoptosis in these cell types
without affecting mature PMNs (10). Groups of these mice
were given dimerizer or were mock treated (treated with mock
injection solution), infected by the i.v. route with 200 CFU of
the parent Y. pestis, and analyzed for viable numbers of bac-
teria in the liver and spleen on day 4 p.i. The depletion of
CD11b Ly6G cells in dimerizer-treated MaFIA mice was
about 95%, and PMNs were not depleted (data not shown).
Figure 6 shows that ablation of Ms/DCs by this alternative
procedure again resulted in significantly lower bacterial bur-
dens in organs.
Interestingly, in mice treated with clodronate-liposomes, the
yopM1 mutant still showed restricted growth compared to the
parent strain, most prominently in the spleen (Fig. 5C), and in
both the liver and spleen, viable numbers of both Y. pestis
strains were controlled. This control correlated with the influx
of PMNs, and PMNs likely are responsible for the growth
deficit of the YopM strain in the mice ablated for nongranu-
locytic myeloid cells. However, because the clodronate-lipo-
some treatment failed to achieve complete depletion, this ex-
periment did not completely rule out an effect of YopM on
nongranulocytic myeloid cells or a role of these cells in con-
trolling bacterial growth.
YopM is required for virulence in bubonic, but not pneu-
monic, plague. The studies so far had indicated that the viru-
lence effect of YopM in systemic plague is directed against
Gr1 inflammatory cells to promote bacterial growth. To ex-
tend our information to peripheral phases of plague, we tested
the importance of YopM for lethality in bubonic and pneumo-
nic plague. We used the fully virulent Pgm Y. pestis CO92.S6
strain for these studies and also deleted YopM and its pro-
moter in this strain background, creating the yopM2 strain
CO92.S19. It should be noted that the yopM genes of Y. pestis
KIM5 and CO92 are identical. The LD50 of the yopM2 strain
by the i.n. route was similar to that for CO92.S6 (Table 3),
indicating that YopM is not required for lethality of pneumo-
nic plague. It remains to be determined whether the progres-
sion of colonization and pathology in pneumonic plague is
unaltered by the absence of YopM in the infecting Y. pestis.
For experimental bubonic plague, we tested virulence by i.d.
injection, as happens during infection by fleabite (51). By this
route, the yopM2 mutant strain was 25-fold less lethal than
the parent Y. pestis (Table 3). These results show that YopM is
required for full lethality in bubonic plague, but not pneumo-
nic plague.
The influx of inflammatory cells into lungs does not occur
before 36 to 48 h p.i. in pneumonic plague (27), but it was not
known whether there is a rapid inflammatory response in bubonic
plague. We hypothesized that PMNs would be recruited early in
infected skin if they are a major target cell for YopM’s virulence
effect and if YopM is required for virulence early in bubonic
plague. To test this idea, we harvested the skin surrounding the
infection site at 8 h p.i. for histopathological analysis. For com-
parison, the lungs of mice infected by the i.n. route were also
evaluated. Figure 7 shows that a robust influx of PMNs was under
way by 8 h p.i. in the skin of mice infected with either Y. pestis
strain. In contrast, there was no inflammation present in the lungs
at this time or at 24 h p.i. for mice infected by the i.n. route (Fig.
7 and data not shown). These findings are consistent with a re-
quirement for YopM to counteract the innate inflammatory re-
sponse in bubonic but not pneumonic plague.
DISCUSSION
The plague virulence protein YopM is known to be deliv-
ered to host cells upon contact and in some way to counteract
KIM5-3002 (yopM1 mutant) or the parent strain KIM5. The same doses of liposomes were also given to the mice on day 1 p.i. (A to C) On days
1, 2, and 3 p.i., the percentages of Ms/monocytes (A) and PMNs (B), and numbers of CFU (C) in spleens and livers were determined.
Representative flow cytometric scatter plots illustrating the discrimination among cell populations in the spleens from a noninfected mock-treated
mouse (top plot) and a noninfected mouse ablated of nongranulocytic myeloid cells (bottom plot) on day 1 (d1) of the experiment are shown to
the right of panel A. The data in the graphs represent the averages plus SDs (error bars) for six mice per datum point in panels A and B and from
nine and six mice per datum point for the spleen and liver, respectively, in panel C, pooled from replicate experiments. Values that are significantly
different (P  0.01) in the M/monocyte-ablated and mock-treated groups of mice infected with KIM5-3002 are indicated (††). Values that are
significantly different in the M/monocyte-ablated and mock-treated groups of mice infected with KIM5 are indicated as follows: #, P  0.05; #
#, P  0.01. Values that are significantly different (P  0.01) in the mock-treated mice infected with KIM5 and KIM5-3002 are indicated ().
Values that are significantly different in the Gr1 cell-ablated mice infected with KIM5 and KIM5-3002 are indicated as follows: , P  0.05; ,
P  0.01. (D) Histopathology on day 3 p.i. in the livers of the M/monocyte-ablated and mock-treated mice infected with Y. pestis KIM5 or
KIM5-3002. Bars, 50 	m.
FIG. 6. Conditional ablation of Ms/DCs by Fas-induced apoptosis in
transgenic MaFIA mice also restricted growth of Y. pestis KIM5. MaFIA
mice were given daily i.v. injections of dimerizer drug AP20187 or mock
injection solution for 5 days and then were allowed to rest 2 days before
being infected with 200 CFU of Y. pestis KIM5. The numbers of CFU in
the liver and spleen on day 4 p.i. were measured. Data (averages plus SDs
[error bars]) are from six mice per treatment, pooled from replicate
experiments. Values that are significantly different (P  0.01) from the
values for the mock-treated groups are indicated ().
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innate defenses, but this protein has been refractory to in vitro
attempts to identify a phenotype resulting from its delivery. In
contrast, YopM has a strong virulence phenotype in vivo, in
which parent Y. pestis KIM5 and the yopM1 mutant KIM5-
3002 show distinct dynamics for viable numbers in organs of
mice infected systemically. We have been exploiting this phe-
notype to identify the innate immune cells that are affected.
Previous studies by workers in our research laboratory re-
vealed a YopM-associated depletion of NK cells from the
spleen and blood of mice infected by the i.v. route, and this
depletion was accompanied by decreased production of several
proinflammatory cytokines, including IL-1, IL-12, IL-15, and
IL-18 by F4/80 cells (Ms and monocytes), and of IFN- by
NK cells (25). In the present study, we assessed the importance
of NK cells early in systemic plague and found no effect of NK
cell ablation on growth of either the parent Y. pestis or the
YopM mutant strain. In contrast, ablation of Gr1 cells sig-
nificantly relieved the growth defect of the YopM mutant,
and the mutant and parent strains caused similarly necrotic
lesions in liver. The relevant Gr1 cells probably were PMNs,
because ablation of Ms/DCs, including Gr1 inflammatory
monocytes, had the opposite effect, of inhibiting growth of
both strains accompanied by significantly fewer, smaller, and
less necrotic lesion sites in liver. However, we cannot rule
between PMNs and inflammatory monocytes in limiting
growth of the Y. pestis yopM1 mutant strain in the spleen, and
both may be involved. Therefore, we hypothesize that YopM
interferes with innate immunity through Gr1 cells instead of
NK cells and that Ms/DCs provide a protective environment
for Y. pestis in a YopM-independent manner.
Our previous work had mainly analyzed immune cell popu-
lations in the spleen. However, the liver is the other organ
predominantly infected in the first 3 days of systemic plague,
and growth dynamics of Y. pestis in the liver are similar to those
in the spleen despite the distinct immune microenvironments
in these two organs. For example, the liver, more than the
spleen, is a focus for immune surveillance by NK-T cells, which
can release IL-4 explosively and other key Th2 cytokines, such
as IL-13, in addition to massive amounts of IFN- (5, 40). In
our previous study (25), we had not evaluated leukocyte pop-
ulation dynamics in the liver due to the difficulty of separating
leukocytes from hepatocytes. In this work, we combined and
modified protocols originally developed for obtaining leuko-
cytes from the colon (47) to obtain high-purity preparations of
leukocytes from the liver, and these were analyzed by flow
cytometry alongside leukocytes from the spleen in mice in-
fected with Y. pestis KIM5 or KIM5-3002. Several tissue-selec-
tive changes were found. In the spleen, only NK1.1 CD3 NK
cells and not other classes of NK cells displayed YopM-specific
depletion. In contrast, in the liver, there was little to no deple-
tion of either classic NK cells (NK1.1 CD3) or NK-T cells in
mice infected by either the parent or YopM Y. pestis strains.
This finding indicated that the virulence effect of YopM in the
FIG. 7. Histology in skin after i.d. infection and lung after i.n. infection with Y. pestis CO92.S19 (yopM2 mutant) or with the parent strain,
CO92.S6. Tissue samples were harvested from uninfected mice and from mice infected by the fully virulent Y. pestis CO92.S6 and yopM2
derivative 8 h after i.d. infection with ca. 200 CFU (actual doses, 216 CFU for CO92.S6 and 163 CFU for CO92.S19) or 8 h after i.n. infection with
5,100 CFU of CO92.S6 and 4,000 CFU of CO92.S19. (Top panels) Skin near the infection site; (bottom panels) lung shown at fourfold-lower
magnification than for skin. Bars, 50 	m (top panels) and 100 	m (bottom panels).
TABLE 3. Virulence in 6- to 8-week female C57BL/6 mice of
Y. pestis strains used in this study
Y. pestis
strain
Infection
route
No. of
expts
No. of
mice/group
Total
no. of
mice
LD50a
CO92.S6 i.n. 2 7 or 8 61 14  18 (1–182)
i.d. 2 6 or 7 32 17  17 (3–97)
CO92.S19 i.n. 2 4–8 45 39  18 (12–75)
i.d. 3 6 66 409  178 (214–1,118)
a Values are the averages  standard errors of the means, with 95% confi-
dence limits given in parentheses.
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liver was not manifested as a net loss of NK cells but did not
rule out the possibility that these cells were lost and rapidly
replenished due to preferential homing of NK cells to the liver
(26). To rule on whether NK1.1 cells were critical for the
virulence effect of YopM, we tested whether ablation of NK
cells would relieve the growth defect of the YopM mutant
and found no effect of ablation on viable bacterial numbers of
either the parent or the mutant in either the liver or spleen.
This finding indicated that NK cells are redundant for YopM’s
pathogenic mechanism or that NK cell depletion by YopM is
an irrelevant secondary effect of YopM.
Interestingly, monocytes failed to be recruited as robustly
into the spleens of mice infected with parent Y. pestis as in mice
infected by the YopM mutant. This effect did not occur in the
liver. The difference in monocyte influx could contribute to the
YopM-dependent NK cell depletion in the spleen, since M-
like cells are major producers of IL-15, a cytokine that is
critical for the maintenance of viability of circulating NK cells
(46). DCs have also been implicated as having a role in NK cell
survival and proliferation through cell-to-cell contact and pro-
duction of cytokines, including IL-15 (64), and a YopM-in-
duced failure in the cross talk between NK cells and DCs could
underlie NK cell depletion in the spleen by YopM. An effect of
YopM that decreases IL-15 production by PMNs could also
contribute to the YopM-associated loss of NK cells from the
spleen. These speculations need to be tested in future work;
however, we have confirmed the importance of Ms/DCs for
NK cell survival in our system. Depletion of ca. 70% of M-
like cells by clodronate-liposomes eliminated the influx of
monocytes into the spleen and liver in mice infected with the
YopM mutant and ablated 80% of the DCs in the spleen,
while eliminating DC influx into the liver. Concomitantly,
there was an essentially complete loss of NK1.1 DX5 NK
cells in both organs (data not shown).
We next examined populations of DCs for changes that
might correlate with YopM’s effect on bacterial growth, be-
cause of the well-established frontline surveillance function of
DCs for invading microorganisms or microbial products (3).
There is evidence that Y. pestis selectively engages Ms, DCs,
and PMNs for Yop injection through the T3SS (34), and the
migration of DCs to draining lymph nodes is inhibited when
the infecting Y. pestis strain contains the virulence plasmid
carrying genes encoding Yops (63). We monitored the num-
bers of three major subgroups of DCs in mice infected by the
parent or YopM Y. pestis. In the spleen, only the numbers of
CD8 DCs displayed a YopM-specific change, decreasing
fourfold by day 4 p.i. These DCs are located in the T-cell area,
where they can internalize apoptotic cells, selectively present
antigens to both CD4 and CD8 T cells, and elicit a Th-1
response through production of IL-12 and IFN- (2). In the
liver, all three subgroups of DCs decreased in numbers when
the infecting Y. pestis strain contained YopM. However, the
YopM-related changes in the numbers of CD8 DCs in
spleens or DCs in livers only became significant relatively late
in infection (days 4 to 5 p.i.) compared to the time when the
growth difference between the two Y. pestis strains became
significant (day 2 or 3 p.i.). Accordingly, although DCs likely
are important in plague and YopM may have a role in modu-
lating the function of these cells, an inhibitory effect of YopM
on another cell type is likely to be responsible for promoting
early bacterial growth.
PMNs and inflammatory monocytes have received little in
vitro study compared to Ms for their role in the pathogenic
mechanisms of Yops, although PMNs are thought to be im-
portant in controlling bacterial numbers early in plague (22,
52). In vitro, Y. pestis KIM5 selectively injects Yops into PMNs
as well as Ms and DCs among splenic leukocytes (34). We
found no difference in the numbers of PMNs in the livers and
spleens of mice infected with the parent strain of Y. pestis or
the YopM mutant, indicating that YopM does not affect the
recruitment of PMNs. Ablation of PMNs and other Gr1 cells
allowed a significant increase in the bacterial burden when
mice were infected with the YopM Y. pestis strain, and lesions
in livers due to the YopM bacteria resembled those from
mice infected with the parent strain. These findings showed
that Gr1 cells are dominant in restricting the growth of
YopM Y. pestis. Depletion of these cells also allowed some
increased growth of the parent Y. pestis, likely because even the
parent strain does not neutralize 100% of the Gr1 cells.
PMNs were strongly depleted by the anti-Gr1 (Ly6G/Ly6C)
treatment and are a prime candidate for a cell type that is
important for controlling bacterial proliferation in both the
liver and spleen. However, the anti-Gr1 treatment also elimi-
nated the influx of Ly6G Ms/monocytes into the spleen and
delayed the influx into the liver, probably due to the robust
expression of Ly6C on inflammatory monocytes (20). Accord-
ingly, these experiments pointed to the involvement of PMNs
and/or inflammatory monocytes in the manifestation of the
growth phenotype of YopM Y. pestis. In contrast to the effect
of anti-Gr1, treatment of mice with clodronate-liposomes to
deplete Ms/DCs curtailed growth of both Y. pestis strains. As
reported by other groups (4, 24), treatment with clodronate-
liposomes did not deplete PMNs. Taken together, these data
support the hypothesis that PMNs are critical effectors for the
in vivo growth defect of YopM Y. pestis; in contrast, Ms
and/or DCs promote bacterial growth in a YopM-independent
manner during the first few days of systemic plague as previ-
ously suggested (33). Studies are currently under way to assess
the role of inflammatory monocytes in controlling growth of
YopM Y. pestis.
In pneumonic plague, recruitment of PMNs to the lungs and
local production of proinflammatory cytokines and chemo-
kines are delayed and do not occur for 36 to 48 h (8). We
confirmed this result for the influx of inflammatory cells (Fig.
7 and data not shown for other times p.i.). In contrast, we
found that there was a robust inflammatory response in skin as
early as 8 h following i.d. infection mimicking fleabite. Consis-
tent with an early difference in the inflammatory character
between the two types of plague, there is a growing number of
pathogenic properties that are required for full virulence in
bubonic, but not pneumonic, plague (11, 12, 18). Also, YopM
was required for lethality of Y. pestis CO92 in experimental
bubonic, but not pneumonic, plague in mice, consistent with
our hypothesis that YopM functions to counteract the effect of
PMNs on bacterial growth. There was no noticeable difference
in the magnitude of PMN recruitment to the infected dermis
between mice infected with the parent strain or the yopM2
mutant, consistent with our observations in the liver and spleen
with Y. pestis KIM5 and also with studies using a peritoneal
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infection model to quantify PMN influx (Z. Ye, D. A. Cohen,
A. M. Kaplan, and S. C. Straley, unpublished data). Accord-
ingly, we believe that YopM’s major effect on PMNs is not on
their influx into infected organs but on their inflammatory
function. A recent study has shown that in vitro, Y. pestis KIM5
shows the same time course of killing by human PMNs as does
Y. pestis KIM6 lacking the virulence plasmid that encodes
components of the T3SS and Yops (55), indicating that YopM
and other Yops may not function directly to enhance survival
within PMNs.
We previously showed that there is a YopM-associated de-
crease in net message expression for proinflammatory cyto-
kines in F4/80 cells (Ms/monocytes) as early as day 2 p.i.
(25). In part, this could have reflected a smaller contribution of
inflammatory monocytes to the F4/80 population analyzed
from mice infected by the parent Y. pestis KIM5 compared to
the YopM mutant. However, it likely also reflected an early
effect of YopM delivered to resident Ms/DCs and raised the
possibility that YopM indirectly affects PMNs by compromis-
ing cytokine production of Ms and DCs. Our attempt to test
this idea by ablating nongranulocytic myeloid cells was com-
plicated by the curtailed growth of both parent and mutant Y.
pestis and the incomplete ablation by liposome-encapsulated
clodronate. Discerning which cell type is the primary target for
YopM’s pathogenic mechanism thus is complicated, and likely
more than one type is involved in mediating the overall viru-
lence effect of YopM, possibly through cytokine cross talk that
provides reciprocal stimulation of innate immune cells, like
PMNs, Ms, and DCs (23, 35, 39, 54).
Figure 8 shows our model for how YopM could influence
the early host response during systemic plague. Early after
injection by fleabite, Y. pestis may be taken into resident
dermal Ms and DCs, which support intracellular replica-
tion that amplifies the infectious dose, while protecting the
yersiniae from attack by PMNs. Within the protective intra-
cellular niche, the bacteria express genes, such as those
genes encoding components of the T3SS and Yops. A local
proinflammatory environment develops and recruits PMNs
and monocytes. After release from the resident cells, the
bacteria are now armed to survive encounters with infil-
trated PMNs and inflammatory monocytes. Although the
monocytes may also contribute a growth-permissive niche
for the yersiniae, these cells could potentially contribute to
killing the bacteria, and there is a YopM-dependent de-
crease in recruitment of these cells into the spleen. If the
yersiniae lack YopM, PMNs will clear the bacteria. When
the yersiniae express YopM, some function of PMNs will be
blocked and bacterial growth will be unchecked.
Ongoing studies are aimed at identifying that function and
its underlying mechanism and clarifying the roles played by
monocytes, Ms, and DCs. Further work is needed to under-
stand how the distinct responses of the liver and spleen arise
and operate in host defense during plague. This study is the
first to have documented these differences and has provided a
foundation for future studies.
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